Quetiapine

Generic Name
Quetiapine
Brand Names
Seroquel
Drug Type
Small Molecule
Chemical Formula
C21H25N3O2S
CAS Number
111974-69-7
Unique Ingredient Identifier
BGL0JSY5SI
Background

Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivi...

Indication

Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in comb...

Associated Conditions
Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Associated Therapies
-
Clinical Trials
Related News

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

Phase 2
Completed
Conditions
Schizoaffective Disorder
Schizophrenia
Interventions
Drug: quetiapine
First Posted Date
2006-03-01
Last Posted Date
2015-04-17
Lead Sponsor
Manhattan Psychiatric Center
Target Recruit Count
60
Registration Number
NCT00297947
Locations
🇺🇸

Manhattan Psychiatric Center, New York, New York, United States

🇺🇸

Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States

Quetiapine Augmentation for Treatment-resistant PTSD

First Posted Date
2006-02-15
Last Posted Date
2019-10-16
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
124
Registration Number
NCT00292370
Locations
🇺🇸

Tuscaloosa VAMC, Tuscaloosa, Alabama, United States

🇺🇸

Ralph H. Johnson, Charleston, South Carolina, United States

🇺🇸

Birmingham VA Medical Center, Birmingham, Alabama, United States

Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms

Phase 3
Completed
Conditions
Bipolar Disorder
First Posted Date
2006-01-16
Last Posted Date
2009-03-13
Lead Sponsor
Lindner Center of HOPE
Target Recruit Count
40
Registration Number
NCT00277667
Locations
🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

Phase 1
Completed
Conditions
Dyskinesia, Drug-Induced
First Posted Date
2005-11-21
Last Posted Date
2013-06-06
Lead Sponsor
University of California, San Diego
Target Recruit Count
250
Registration Number
NCT00255879
Locations
🇺🇸

University of California, San Diego Division of Geriatric Psychiatry, San Diego, California, United States

Fast Titration Of Quetiapine Versus Currently Approved Titration

Phase 3
Completed
Conditions
Psychotic Disorders
First Posted Date
2005-11-17
Last Posted Date
2011-01-26
Lead Sponsor
AstraZeneca
Target Recruit Count
150
Registration Number
NCT00254813
Locations
🇳🇴

Research Site, Ålesund, Norway

Venlafaxine Augmentation in Treatment Resistant Depression

Phase 4
Completed
Conditions
Depression
Interventions
Drug: Venlafaxine
Drug: Quetiapine
First Posted Date
2005-11-15
Last Posted Date
2015-04-08
Lead Sponsor
Max-Planck-Institute of Psychiatry
Target Recruit Count
126
Registration Number
NCT00253266
Locations
🇩🇪

Max Planck Institute of Psychiatry, Munich, Bavaria, Germany

Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders

Phase 3
Completed
Conditions
Bipolar Disorder
First Posted Date
2005-11-11
Last Posted Date
2008-06-04
Lead Sponsor
Mood Disorders Center of Ottawa
Target Recruit Count
100
Registration Number
NCT00252226
Locations
🇨🇦

Mood Disorders Center of Ottawa, Ottawa, Ontario, Canada

Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
First Posted Date
2005-10-12
Last Posted Date
2014-06-06
Lead Sponsor
Yale University
Registration Number
NCT00237861

Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)

Phase 4
Completed
Conditions
PTSD
Interventions
Drug: Placebo
Drug: Quetiapine
First Posted Date
2005-10-12
Last Posted Date
2008-02-21
Lead Sponsor
Ralph H. Johnson VA Medical Center
Target Recruit Count
80
Registration Number
NCT00237393
Locations
🇺🇸

NM VA Healthcare System, Albuquerque, New Mexico, United States

🇺🇸

Ralph H. Johnson VAMC, Charleston, South Carolina, United States

Quetiapine for Cocaine Use and Cravings

First Posted Date
2005-10-04
Last Posted Date
2024-04-19
Lead Sponsor
Seattle Institute for Biomedical and Clinical Research
Target Recruit Count
42
Registration Number
NCT00232336
Locations
🇺🇸

VA Puget Sound Health Care System, American Lake Division, Tacoma, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy